Technology Sheets

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Donec ac odio tempor orci dapibus ultrices in iaculis nunc. Vitae sapien pellentesque habitant morbi tristique senectus. 

1 min read

Research Cell Bank Development

April 13, 2019

For nearly 20 years, Selexis has been helping its partners predictably, rapidly and cost-effectively generate life-saving biologic medicines and vaccines. Its SUREtechnology Platform™ is being used by  clients worldwide, resulting in more than 119 biologic drug products in clinical and commercial manufacturing. Selexis is able to generate stable and high-expressing (2–7 g/L for MAbs, >1.5g/L for bispecific antibodies, fed batch in shake flask, >10 g/L in bioreactor) research cell banks (RCBs) in as little as 14 weeks.

View PDF

Keywords: cell line development clonal cell line SUREtechnology recombinant protein expression research cell bank clonal cell lines